Chen Y P, Zhu W F, Lin J Y, He T M, Ma H M, Lu J P, Ye X A, Xu C W, Chen G
Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, China.
Zhonghua Bing Li Xue Za Zhi. 2016 Dec 8;45(12):825-830. doi: 10.3760/cma.j.issn.0529-5807.2016.12.003.
To investigate the relationship between expression of PDGFRA/CMYC and clinicopathologic features of extranodal NK/T-cell lymphoma. Fifty-four cases of extranodal NK/T-cell lymphoma were included in the study.Immunohistochemistry was used to detect the expression of CD20, CD2, CD3, CD56, TIA1, GrB, Ki-67, PDGFRA and CMYC.In situ hybridization was performed to detect the presence of EBV encoded small RNA (EBER). Fifty cases of nasopharyngeal mucosal lymphoid tissue hyperplasia were used as normal control. Among 54 cases of ENKTL, CD2, CD3, GrB, and TIA1 were expressed in all the tumors. CD56 was expressed in 47 cases (81.0%) and CD20 was not detectable in any cases. Ki-67 proliferative index expression of > 60% was found in 45 cases (83.3%). In situ hybridization for EBER was positive in all cases (100%). The positive expression rates of PDGFRA and CMYC in extranodal NK/T-cell lymphomas were 51.9%(28/54) and 53.7%(29/54), respectively, much higher than those in nasopharyngeal mucosal lymphoid tissue hyperplasia (0, <0.05). There was a positive correlation between PDGFRA and CMYC (=0.295, <0.05). The expression of CMYC was correlated with clinical efficacy (<0.05), but not with gender, age, Ann Arbor stage, B symptoms and therapeutic regimen (all >0.05). The expression of PDGFRA was correlated with B symptoms (<0.05), while not with gender, age, Ann Arbor stage, therapeutic regimen and clinical efficacy (all >0.05). The co-expression of PDGFRA and CMYC was not correlated with gender, age, Ann Arbor stage, B symptoms, therapeutic regimen and clinical efficacy (>0.05). Univariate analysis showed that the stage, clinical efficacy, CMYC protein and the co-expression of PDGFRA and CMYC were significantly correlated with the prognosis. The overall survival of the patients with CMYC positive expression was shorter than of that of the patients with negative expression (<0.05). Multivariable Cox regression analysis further confirmed that clinical stage, CMYC protein expression, and the co-expression of PDGFRA and CMYC were independent prognostic factors in patients with extranodal NK/T-cell lymphoma. CMYC protein, and the co-expression of PDGFRA and CMYC can be as an independent prognostic factor in patients with extranodal NK/T-cell lymphoma and influence the prognosis of patients.
探讨血小板衍生生长因子受体α（PDGFRA）/原癌基因c-MYC（CMYC）的表达与结外NK/T细胞淋巴瘤临床病理特征之间的关系。本研究纳入54例结外NK/T细胞淋巴瘤患者。采用免疫组织化学法检测CD20、CD2、CD3、CD56、颗粒酶B（GrB）、TIA1、Ki-67、PDGFRA和CMYC的表达。采用原位杂交法检测EB病毒编码小RNA（EBER）的存在情况。选取50例鼻咽黏膜淋巴组织增生患者作为正常对照。在54例结外NK/T细胞淋巴瘤中，所有肿瘤均表达CD2、CD3、GrB和TIA1。47例（81.0%）表达CD56，所有病例均未检测到CD20表达。45例（83.3%）Ki-67增殖指数表达>60%。EBER原位杂交所有病例均为阳性（100%）。结外NK/T细胞淋巴瘤中PDGFRA和CMYC的阳性表达率分别为51.9%（28/54）和53.7%（29/54），显著高于鼻咽黏膜淋巴组织增生（0，P<0.05）。PDGFRA与CMYC呈正相关（r=0.295，P<0.05）。CMYC的表达与临床疗效相关（P<0.05），但与性别、年龄、Ann Arbor分期、B症状及治疗方案均无关（均P>0.05）。PDGFRA的表达与B症状相关（P<0.05），而与性别、年龄、Ann Arbor分期、治疗方案及临床疗效均无关（均P>0.05）。PDGFRA与CMYC的共表达与性别、年龄、Ann Arbor分期、B症状、治疗方案及临床疗效均无关（P>0.05）。单因素分析显示，分期、临床疗效、CMYC蛋白以及PDGFRA与CMYC的共表达与预后显著相关。CMYC阳性表达患者的总生存期短于阴性表达患者（P<0.05）。多因素Cox回归分析进一步证实，临床分期、CMYC蛋白表达以及PDGFRA与CMYC的共表达是结外NK/T细胞淋巴瘤患者的独立预后因素。CMYC蛋白以及PDGFRA与CMYC的共表达可作为结外NK/T细胞淋巴瘤患者的独立预后因素并影响患者预后。
